A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
ApexOnco Front Page
Recent articles
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Ideate-Lung02 goes on global clinical hold.
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
On a cross-trial basis varegacestat beats Ogsiveo.
No fewer than four ADCs with this target start human testing.
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
